Literature DB >> 18367253

Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease.

Paloma Bermejo1, Sagrario Martín-Aragón, Juana Benedí, Cristina Susín, Emanuela Felici, Pedro Gil, José Manuel Ribera, Angel M Villar.   

Abstract

Multiple pathogenic factors may contribute to the pathophysiology of Alzheimer's disease (AD). Peripheral markers have been used to assess biochemical alterations associated with AD and mild cognitive impairment (MCI) involved in its pathophysiology. The present study was conducted to evaluate inflammatory peripheral markers in elderly patients with MCI, patients with AD and normal elderly subjects. We measured plasma levels of different cytokines (IL-6, TNF-alpha and IFN-alpha) and platelet levels of cyclooxigenase-2 (COX-2) from 34 patients with MCI, 45 patients with AD and 28 age-matched control subjects. MCI and AD patients showed similarities in TNF-alpha and COX-2 levels, and differences in IL-6 and INF-alpha. Whereas augmented IL-6 levels have been found in AD patients, a significant increase in INF-alpha has been detected only in patients with MCI possibly associated with the depression stage frequently found in cognitive impairment. In conclusion, inflammatory response may be an early factor in AD development and these changes in circulating markers are possibly related to the progression of MCI to AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367253     DOI: 10.1016/j.imlet.2008.02.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  55 in total

Review 1.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

Review 2.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

Review 3.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

Review 4.  BioAge: toward a multi-determined, mechanistic account of cognitive aging.

Authors:  Correne A DeCarlo; Holly A Tuokko; Dorothy Williams; Roger A Dixon; Stuart W S MacDonald
Journal:  Ageing Res Rev       Date:  2014-09-30       Impact factor: 10.895

Review 5.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 6.  Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.

Authors:  Subbiah Pugazhenthi; Limei Qin; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-05-06       Impact factor: 5.187

Review 7.  Risk factors for the progression of mild cognitive impairment to dementia.

Authors:  Noll L Campbell; Fred Unverzagt; Michael A LaMantia; Babar A Khan; Malaz A Boustani
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

8.  Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution.

Authors:  Beatrice Arosio; Luigina Mastronardi; Carlo Vergani; Giorgio Annoni
Journal:  Int J Alzheimers Dis       Date:  2010-07-20

9.  Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.

Authors:  Onofre Combarros; Cornelia M van Duijn; Naomi Hammond; Olivia Belbin; Alejandro Arias-Vásquez; Mario Cortina-Borja; Michael G Lehmann; Yurii S Aulchenko; Maaike Schuur; Heike Kölsch; Reinhard Heun; Gordon K Wilcock; Kristelle Brown; Patrick G Kehoe; Rachel Harrison; Eliecer Coto; Victoria Alvarez; Panos Deloukas; Ignacio Mateo; Rhian Gwilliam; Kevin Morgan; Donald R Warden; A David Smith; Donald J Lehmann
Journal:  J Neuroinflammation       Date:  2009-08-23       Impact factor: 8.322

10.  Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology.

Authors:  Yuyan Zhu; Demian Obregon; Huayan Hou; Brian Giunta; Jared Ehrhart; Frank Fernandez; Takashi Mori; William Nikolic; Yangbing Zhao; Dave Morgan; Terrence Town; Jun Tan
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.